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Abstract: Pathologic calcification leads to structural deterioration of implant materials via stiffening,
stress cracking, and other structural disintegration mechanisms, and the effect can be critical for
implants intended for long-term or permanent implantation. This study demonstrates the potential of
using specific metal ions (MI)s for inhibiting pathological calcification in polyurethane (PU) implants.
The hypothesis of using MIs as anti-calcification agents was based on the natural calcium-antagonist
role of Mg2+ ions in human body, and the anti-calcification effect of Fe3+ ions in bio-prosthetic
heart valves has previously been confirmed. In vitro calcification results indicated that a protective
covering mesh of MI-doped PU can prevent calcification by preventing hydroxyapatite crystal growth.
However, microstructure and mechanical characterisation revealed oxidative degradation effects
from Fe3+ ions on the mechanical properties of the PU matrix. Therefore, from both a mechanical
and anti-calcification effects point of view, Mg2+ ions are more promising candidates than Fe3+
ions. The in vitro MI release experiments demonstrated that PU microphase separation and the
structural design of PU-MI matrices were important determinants of release kinetics. Increased phase
separation in doped PU assisted in consistent long-term release of dissolved MIs from both hard and
soft segments of the PU. The use of a composite-sandwich mesh design prevented an initial burst
release which improved the late (>20 days) release rate of MIs from the matrix.
Keywords: calcification; magnesium; metal ion; Von Kossa method; Alizarin red S staining;
anti-calcification; nanofibre matrix; hydroxyapatite
1. Introduction
Calcification is a normal, or rather physiological event (physiological mineralization) in the
formation of hard tissues (bones and teeth). The main product of calcification is a hydroxyapatite (HAP)
crystal, Ca10(OH)2(PO4)6 which provides structural integrity to the bone. Under normal conditions,
calcium exists in a metastable equilibrium with dissolved phosphate species [1]. Any skewness in
equilibrium can result in calcification of functional soft tissues and synthetic implant materials in a
process known as pathologic calcification [2–4]. Pathologic calcification can be of two types; dystrophic
and metastatic [5]. Dystrophic calcification is commonly observed as calcific deposits in cells and the
extracellular matrix of damaged or diseased tissues [6]. In synthetic implants, dystrophic calcification
is dependent on numerous factors, namely material properties, device design, surface chemistry,
host biological system, and stress concentration etc. On the other hand, in metastatic calcification,
the calcific deposits start forming deep within the biological tissue (intrinsic calcification). This occurs
due to disruption in mineral metabolism, or disproportionate calcium or phosphorus levels [7].
Deposition of calcium crystals has been widely reported in soft tissue implant devices like heart
valves, vascular grafts, stents, cardiac assist devices, and blood pumps etc. [7–10]. Calcification can
lead to structural deterioration of implant materials via stiffening, stress cracking and other structural
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disintegration mechanisms, and the effect can be critical for implants intended for long-term or
permanent implantation. Polyurethanes (PU)s are extensively used synthetic materials for heart valve
implants and artificial blood pump applications, and hence calcification is a major concern for their
intended application. Calcification reduces the fatigue life and elasticity of the PU, which ultimately
can translate into poor long-term performance of the implant [5]. Hard HAP crystals can induce
fracture failures, even in metallic stent implants [11]. The fatigue is much more severe in the case of
angulated small diameter lesions where calcified hard regions cyclically rub against already stressed
stent struts [11]. The hardness of calcium deposits has been found to be similar to that of metals such
nickel and iron (710 MPa or 72.4 Vickers) [12], which directly indicates the severity of metal fatigue
under continuous pulsatile conditions.
Despite the clinical importance of the problem, the mechanism of calcification is not yet completely
understood [13–15]. Furthermore, there is no effective treatment therapy still available. Calcification
is a multifactorial process, and hence an effective therapeutic strategy may require drug action at
different stages of calcium phosphate deposition [13,16]. A therapeutic approach involves implantation
of a controlled release drug delivery system that facilitates local, site-specific anti-calcification.
The therapeutic applications of metal ions (MI)s in regenerative medicine and tissue engineering
fields are readily increasing. This increased interest is owed to its low cost, increased stability, and,
relatively lower risk than proteins or genetic engineering techniques [17]. Therefore, numerous
strategies of MI release from polymeric matrices or scaffolds are being designed. PU qualifies well for
versatile medical applications [18–20], owing to its microstructure, which allows easy incorporation
of functional groups and bulk modifications [21]. Several investigations have been performed using
MI release matrices showcasing controlled release and improved therapeutic action at the treatment
site [22–24]. However, the design of MI-loaded polymeric matrices is a critical task, as high MI
concentration can lead to significant systemic toxicity [17]. The design features include an optimum
degree of MI loading and their controlled release at the intended treatment site.
In blood serum, the Mg/Ca ratio of about 0.3 is naturally sufficient to prevent HA precipitation in
the body fluids. A similar role is performed by Mg ions in sea water, by controlling calcite (CaCO3)
growth rate [25]. Aluminium (Al) ions can also delay HA formation by adsorbing onto the surface of
growing HA crystals. Al ions slow the direct precipitation of HA, the transformation of amorphous
calcium phosphate (ACP) to HA, and the growth of HA seed crystals, all in a dose-related manner.
While the divalent Mg ion (Mg2+) is believed to enter the forming HA embryonic nuclei, the smaller,
trivalent Al ion (Al3+) is believed to bind and block active growth sites on the surface of forming HA
crystals, thereby slowing apatite proliferation. Also, aluminium chloride (AlCl3) has been claimed to
prevent elastin fibre calcification through permanent structural alteration in the elastin molecule [7].
Ferric ions (Fe3+) have also been reported to inhibit the progression of calcification via the generation
of reactive oxygen species and oxidative stress mechanisms in vascular tissues [26]. Vasudev et al.
proposed that Fe3+ ions slowed down the calcification process by the inhibition of HAP formation,
while Mg2+ ions disrupted the growth of HAP crystals by replacing Ca2+ ions [27]. It was also
hypothesised that both Fe3+ and Mg2+ ions can inhibit formation of alkaline phosphate which acts as a
substrate for HAP crystal binding.
Magnesium is the second most abundant intracellular cation (next to potassium), and the fourth
most abundant cation in the body [28,29]. Magnesium is involved in many essential physiological,
biochemical and cellular processes regulating cardiovascular function, such as contraction and
dilation, growth and inflammation, production of vasoactive agents, and protein and nucleic
acid synthesis [30,31]. Magnesium is considered nature’s physiological calcium blocker [32].
Direct relationships between low serum levels of magnesium and vascular calcification has been
reported widely in both human and experimental animal studies [33–39]. Several in vitro studies
have shown that magnesium’s inhibitory effect on HAP formation and precipitation, as well as
on the calcification process [40–42], while magnesium deficiency appears to promote vascular
calcification [43]. Magnesium ions can stabilize ACP and thus inhibit the formation of calcium-acidic
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phospholipid–phosphate complexes in metastable calcium phosphate solutions [44,45]. Bennett et al.
found that magnesium was also able to inhibit calcium pyrophosphate dihydrate crystal formation
in-vitro [46]. In another study, aortic segments of rats were incubated in the absence and presence
of MgCl2 in a calcification medium with elevated phosphate concentrations [47]. The degree of
calcification was significantly decreased in the aortic rings incubated in the presence of magnesium.
The exact underlying antagonist mechanism of magnesium has not been resolved. However,
the reported studies support the use of Mg2+ ion as a potential drug delivery agent for reducing
implant calcification in a more physiologic manner. Magnesium-based compounds also have the
additional advantage of being much cheaper to use than some newer alternative drugs. However,
the optimal level of release rate and the Mg2+ ion concentration are some concerns that remain to
be determined.
In this study, we reported on the design and comprehensive performance evaluation of MI-loaded
nanofibre matrices for the inhibition of calcification, in an in vitro study. MIs selected for the current study
(Mg2+ and Fe3+) were based on their easy availability in the form of commercial salts (MgSO4, MgCl2,
FeCl3), minimal toxicity levels, and fair solubility in organic solvents used for PU nanofibre spinning.
2. Results and Discussion
2.1. Morphological Analysis
The surface analysis of all the matrices (PU: undoped control sample, PU-MS: MgSO4-loaded
sample, PU-MC: MgCl2-loaded sample, PU-FC: FeCl3-loaded sample) showed a random fibre
distribution on the surface with average fibre diameter of 820 ± 110 nm (Figure 1). There was
insignificant effect of magnesium salt (MgCl2 and MgSO4) doping on fibre configuration (800 ± 105 nm
and 795 ± 100 nm, respectively) while FeCl3 incorporation resulted in relatively finer fibres
(750 ± 180 nm). The presence of very few salt particles on the PU-MI film surface indicated nearly
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Figure 1. Scanning electron microscopy (SEM) micrographs of electrospun (a) Polyurethane (PU);
(b) MgSO4-loaded sample (PU-MS); (c) MgCl2-loaded sample (PU-MC); and (d) FeCl3-loaded sample
(PU-FC) films.
2.2. Fourier Transform Infra RedAnalysis
The characteristic Fo ier transform infra red (FTIR) spectrum of the control PU sample depicted
hard segmen s (HS) or urethane (779, 1044, 1228, 1529, 1701, 1720, 3323, 3445 cm−1), and soft segments
(SS) or ether (1110, 1367, 2795, 2854, 2933 cm−1) absorption bands (Figure 2). The donor groups (free
N-H of urethane) and acceptor groups (free C=O of urethane, free C-O-C of ether) in the spectrum
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1420–1260 cm−1), and crosslinking reactions (1175 cm−1) [49,50]. However, in our experiments, such 
degradation products were  not  observed  after magnesium  salt doping,  indicating  no  significant 
structural degradation of PU. However, doping of ferric salt (FeCl3) may have resulted in HS chain 
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Figure 2. Fourier transform infra red (FTIR) spectrum of electrospun polyurethane film.
The overall changes which occurred in S after metal salt doping indicated that there was a
simultaneous decrease (free C=O and free N-H) and increase (H-bonded C=O and H-bonded N-H) in
its constituent units (Figures 3–5). This suggested that an increased phase separation (or increased
inter-urethane H-bonding) was favoured after MI incorporation in PU. The observed changes in
the intensity of both ether band (1110 cm−1) and specific urethane bands (3350, 1701 cm−1) were,
respectively, indicative of MI interaction with both SS and HS of the PU. Generally, the PU chain
scissio induced y specific metals was associated with t e generation of new organic co pound
bands viz. carboxylic acid (1700–1630 cm−1; 930 cm− , aldehydes (1740 cm−1), alcohols (3650 cm−1,
1420–1260 cm−1), and crosslinking r actions (1175 cm−1) [49,50]. However, in ur experiments,
such degradation products were not observed after magnesium salt doping, indicating no significant
structural degradation of PU. However, doping of ferric salt (FeCl3) may have resulted in HS chain
scission, as indicated by the formation of a carboxylic acid band at 1670 cm−1 (Figure 4). MI doping
in PU resulted in increased phase separation between HS and SS, as observed from increased
inter-urethane H-bonding within hard domains of the PU matrix. FTIR analyses revealed that MIs
were incorporated in both the HS and SS of the PU, but the exact state (amorphous/crystalline) of
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Figure 3. FTIR spectrum of electrospun control PU and metal ion (MI) loaded PU films in the
2500–4000 cm−1 frequency range.
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The  mechanical  characteristics  of  PU  films  are  primarily  controlled  by  their  chemical 




type  on  the  tensile  behaviour.  PU‐FC  exhibited  a  significant  decrease  (31%)  in  peak  strength 
compared to undoped PU, this was attributed to the observed chain scission phenomenon caused by 
Fe3+  ions  (Section  2.2).  Both  PU‐MC  and  PU‐MS  films  exhibited  minimal  changes  in  strength. 
However, the higher stiffness of Mg2+‐doped PU than undoped‐PU was observed, and attributed to 
higher crosslinking within the polymer chains [51,52]. 
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2.3. echanical Properties
The mechanical char cterist cs of PU films are primarily cont olled by their chemical compositions,
i.e., the ratio between SS and HS, and physical cro s-links formed by H-bonding (urethane-urethane
r urethane- r). As d picted by changes in ur thane H-bonding (Section 2.2), similar changes are
expected i the mechanical properties of PU aft r MI doping. Figu e 6 sh ws the tensile behaviour
of undoped and MI-dop PU fil s. There was a clear differen e in the effe t of MI type on the
tensile behaviour. PU-FC exhibited a significant decrea e (31%) in peak strength compared to undoped
PU, this was attributed to t e observed chain scission phenomeno au ed by Fe3+ io s (Sectio 2.2).
Both PU-MC and PU-MS films exhibited minimal changes in strength. H wev r, the higher stiffness
of Mg2+-doped PU than undoped-PU was observed, and attribut to higher crossli king within t e
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(Figure  7A). The  initial burst  release  (0–24 hr or Phase  1)  signified  instant dissolution of  surface 
deposited salt crystals. The dissolution of even a small portion of these crystals can cause burst release 
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higher burst percentages (31%)  than magnesium salts  (MgCl2 = 22% and MgSO4 = 24%). This was 
attributed  to  the  highly  hygroscopic  nature  of  FeCl3 which  instantly  attracts water molecules  to 





PU phase separation. A nearly consistent  release of MIs over a  long  time period  (18 days)  in  the 
second phase  indicated a  sufficiently high  content of  salt particles present  in both  soft and hard 
domains  of  the  polymer.  The  MI  release  in  this  phase  was  considered  to  be  based  on  the 
physiochemical nature of both HS and SS, with the former acting as a micro‐reservoir while the latter 
acted as ion transport channels [58–60]. Based on Equation (1), a power law fit was performed and 
the diffusion  exponent n was  calculated  for  second phase  release profiles of all MIs.  In order  to 
explain the drug release mechanism by diffusion only, the value of n should be nearly equal to 0.5, 
but in our experiments the value of n < 0.5 was observed, indicating that the diffusion mechanism of 






monolithic  polymer matrices,  as  observed  elsewhere  [22].  PU‐FC  exhibited  insignificant  release 
. - fi .
2.4. etal Ion Release
For thin fil e branes, drug release versus ti e curves are often analysed using the po er
la [18,53] as in Equation (1) belo :
Mt/M∞ = k × tn (1)
where k is a constant related to the characteristics of the matrix system, and is a measure of the release
rate; n is a diffusional exponent which is characteristic of the mode of drug transport through the
matrix (n = 0.5 indicates Fickian diffusion and n = 1 indicates a zero-order release; 0.5 < n < 1 indicates
non-Fickian diffusion; t is time) [54–56].
The release profiles of MIs from solid-sandwich films exhibited a three phase release behaviour
(Figure 7A). The initial burst release (0–24 hr or Phase 1) signified instant dissolution of surface
deposited salt crystals. The dissolution of even a small portion of these crystals can cause burst release
by creating new vacant pore sites for the elution media to come in contact with sub-surface particles [57].
Therefore, the degree of burst release was different for all three salts, with FeCl3 exhibiting higher
burst percentages (31%) than magnesium salts (MgCl2 = 22% and MgSO4 = 24%). This was attributed
to the highly hygroscopic nature of FeCl3 which instantly attracts water molecules to interact with the
film surface and hence dissolve the sub-surface salt particles. After the surface dissolution of drug is
exhausted, Phase 2 of drug release initiates, which is primarily governed by diffusion of the drug from
polymeric matrix. As evident from the release profile, the release rate for second phase (Day 2–20)
was slow and consistent (40–80 µg/cm2/day). This phase represented MI transport through soft
domains (or SS) of the polymer matrix, which is dependent on the degree of PU phase separation.
A nearly consistent release of MIs over a long time period (18 days) in the second phase indicated a
sufficiently high content of salt particles present in both soft and hard domains of the polymer. The MI
release in this phase was considered to be based on the physiochemical nature of both HS and SS,
with the former acting as a micro-reservoir while the latter acted as ion transport channels [58–60].
Based on Equation (1), a power law fit was performed and the diffusion exponent n was calculated for
second phase release profiles of all MIs. In order to explain the drug release mechanism by diffusion
only, the value of n should be nearly equal to 0.5, but in our experiments the value of n < 0.5 was
observed, indicating that the diffusion mechanism of MIs release suffered some retardation in the
system. These observations matched the n values observed in the release of copper and silver ions
from MI-silicone composites [22], indicating that the power law provided a limited insight to the
different mechanisms involved in the MI release kinetics from non-degradable monolithic matrix
systems. By the end of second phase (20 days), nearly half (45–55%) of MIs were released. This was
followed a very slow (6–8 µg/cm2/day) but still consistent Phase 3 over rest of the experimental
duration (day 20–60), suggesting a long-term ion release from monolithic polymer matrices, as observed
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elsewhere [22]. PU-FC exhibited insignificant release during Phase-3 (<2 µg/cm2/day) which was
virtually undetectable. Overall, the MI release profiles of MI-PU films appeared to be connected with
PU microdomain structures, with HS acting as micro-reservoirs which helped to maintain long-term
ion release. The continuous release of MIs also indicated that there was sufficiently high availability
of free MIs which can undergo diffusion through the PU microstructure. This may be attributed to
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es . Also, as the un-doped PU nanofibres were hydr phobic, they could markedly in ibit the
i itial i vasion of the rel ase edium into the MI lo ded nanofibre m sh. The contact ar a of th
release medium thus would be restricted in a superficial region of the nanofibre mesh. This made
the un-doped PU nanofibres behave similarly to an external “bar ier mesh” without even co pletely
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c sist t ( µ cm2/day) long-term (day 20–60) release of MIs from co posite fil s tc i
t i i iff i ( 0.44–0.48, 2 = 0.98) principle.
. . alcificatio
ll the MI doped PU matrices (PU-FC, PU-MC, PU-MS) significantly nhibited calcific eposition
compared to the control PU matrix. Scanning electro microscopy (SEM) imaging indicated that
the lcific deposits were rand mly distributed on the film surface but with varied number and size.
The d posits on PU films were observed as firmly bound spherical crystals (average diame er = 2–6 µm,
Figures 8 and 9) similar to those observed by several inve tigators pr iously [61–65]. These depo its
were not aff ct d by subs quent rinsing and r mai ed adhere t in localised fib interstice as
exp cted in the calcification of porous mesh structures [64,66]. In case of MI-PU films, similar deposits
were observe , but n very sparsely populated and submicron size (average diameter = 0.2–0.8 µm)
configu ations. The small s ze of calcific deposits represented th inhibition of calcium-phosphate
crystal formation in the ini ial stages f nucleation tself [67]. Thus, it ppear evident t at the released
Mg2+ and Fe3+ ions prevented calcification by interrupting the f rmation of proper HAP crystals n
the film surface, as propos d by Vasud v et al. [27].
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Von Kossa and Alizarin Red S staining further confirmed the antagonist effect of Mg2+ and
Fe3+ ions on calcium crystal formation (Figures 10 and 11). Microscopic examinations of the stained
undoped PU films showed areas of calcification distributed randomly on the surface with average
spot size of 0.3 mm × 0.3 mm. The large calcification areas were at a later stage after initiation of
calcium crystal formation, which involves simultaneous cascaded deposition of both Ca2+ and PO43−
ions. On the con rary, no observable calcium aggregated regions were observed in MI-doped PU films,
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Figure 10. Light microscopy of (a) PU; (b) PU-MS; (c) PU-MC; and (d) PU-FC films after Von Kossa
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Figure 11. Light microscopy of (a) PU; (b) PU-MS; (c) PU-M ; and (d) PU-F films after Alizarin ed
staining and calcium solution incubation for 60 days. Dark red-orange spots on the surface indicate
aggregated calcium deposits.
e PU matrices howed sign ficant calcified r gions on the surface, even in th absenc
of dynamic stress, owing to the hi hly porous structure of nanofibre films. FTIR analysis reve led the
abs nce of any intrinsic calcification in the prese ce of MIs, while undoped-PU exhibited traces of
c l ification at the micros ructure level. Since calcification involves the uc eation of both calcium and
phosphate ions [66], the level of calcification was dete ted corresponding to the phosphate io (PO43−)
as the O-P-O bond bending mode at 603 a 562 cm−1 bands [68–70]. The FTIR spectrum showed
prominent peaks at 603 a d 562 cm−1 in PU films, while peaks were absent in MI-PU films (Figure 12).
The rea on behind absence of thes peaks on all PU-MI films could be attributed to the assump ion that
calcific tion was limited to the surface only and did not interact with the microstruc ure of the polymer.
While comparing the agnesium ion (Mg2+) with ferric ion (Fe3+), it appears that the divalent
magnesium had less ‘hard ch racter’ than trivalent ferric ion. Their ionic radii (Fe = 68–71 picometer,
Mg = 72 picometer) are similar. However, an extr mely imp rtant characteristic of MIs to be deter in d
for their use in th PU matrix was their oxidation tendenc (or redox potential) [71–73]. The redox
po ntial of Fe3+ ions (0.77 V) is very high compared to Mg2+ io s (−2.36 V). This indicates a higher
tendency of F 3+ ions to degrade the PU st ucture via the MI xidati mechanism (Section 2.3),
s metal io s with a r dox potential higher than 0.7 have been found to p tentially degrade PU
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elongation and tensile properties [71,74]. Therefore, the use of magnesium ions for inhibiting PU
calcification appears to be a viable option.
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3. aterials and ethods
edical grade segmented thermoplastic polyurethane (PU), Tecoflex® was purchased from
Lubrizol Advanced aterials, Inc. (Ohio, OH, USA) The solvents N,N-dimethylformamide (D F)
and Tetrahydrofuran (THF), 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP), and metal salts (magnesium
sulphate, magnesium chloride, and ferric chloride) were obtained from Sigma-Aldrich Co. (Castle Hill,
Australia). All other chemicals were of analytical grade purchased from Sigma-Aldrich Co.
3.1. Electrospinning and MI Loading
PU pellets were dissolved in DMF/THF (40/60, v/v) solution at concentration of 11% (w/v).
Polyurethane-metal ion (PU-MI) solutions were separately prepared by blending metal salts in 11%
(w/v) PU solution in specific ratios to obtain an equal concentration of MIs in each PU-MI solution
(Table 1). Electrospinning was done using a syringe pump (Harvard Apparatus, MA, USA) and a high
voltage power supply (Spellman High voltage, Hauppauge, NY, USA) at +18 kV potential (Figure 13).
Based on experimental characterization requirements, two geometrical configurations of electrospun
samples were prepared (Figure 14): (a) thick films (100–150 µm) of undoped-PU and PU-MI for FTIR,
morphological, and mechanical characterization; (b) solid-sandwich and composite-sandwich films
(100–150 µm thickness) for MI release and calcification studies. Composite-sandwich films were
produced by loading PU and PU-MI solutions in separate syringes and simultaneously electrospinning
on both sides of PU film. Solid-sandwich films were produced by spinning only PU-MI solutions on
both sides of the PU film.
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(Baltec  SCD50  sputter  coater, Leica Microsystems Pty Ltd., Macquarie Park, Australia)  and  then 
viewed at different magnifications under a scanning electron microscope, SEM Neoscope (JCM‐5000, 
JEOL Pty Ltd., Frenchs Forest, Australia) at a 15‐kV accelerating voltage. Fifteen images per sample 










Figure 13. Schematic of electrospinning setup for developing metal salt-loaded PU films.
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Fig re 14. e rese tatio s o i g cross-sectio of ( ) soli -sa ic ; a ( ) co osite-sa ic
electrospun fil s.
5 ) ere t f - fi -
fi i (J - ,
Frenchs Forest, Australia) t a 15-kV accelerating voltage. Fifteen images er
sample type were analysed and the average diameter of the fibres was calculated from 20
i t r ll si I J ft r ( I , ,
standard deviation (T l ).
3.3. echanical Characterisation
The tensile properties of films were determined using a tensile tester (Model 5967, Instron Pty Ltd.,
Bayswater, Australia). The films were cut into rectangular strips (10 mm × 5 m, n = 20) and tested
at speed of 20 mm/ in up to breaking strength, using a load 100 N load cell. Each strip as
preconditioned by application of 25 cycles at 50 / in and 10 strain li it. The ulti ate tensile
strength, breaking elongation and Young’s odulus ere obtained fro the stress-strain curves.
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3.4. MI Release
The MI release measurements were performed in PBS buffer (pH 7.4) medium. MI-PU film
samples (1 cm × 1 cm, n = 10) were immersed in small glass bottles filled containing 5 mL of the
medium and swirling at 100 rpm on a rotating shaker. At appropriate intervals, 2 mL of medium
was withdrawn from the bottle and tested for released MI content over a period of 60 days. An equal
volume of the fresh dissolution medium was added to the bottle again in order to maintain a constant
volume. The amount of MIs (Fe3+ and Mg2+) released from MI-PU films was measured on an atomic
absorption spectrometer (AAS, SpectrAA 140, Varian Inc., Palo Alto, CA, USA) equipped with a
flame furnace. A hollow cathode lamp was used for the measurement of Fe3+ at 248.3 nm and Mg2+
at 202.6 nm wavelengths. An air/acetylene mixture was used as the flame gas with a flow rate of
3.5 L/min for air and 1.5 L/min for acetylene. Initially, a linear calibration curve for both MIs was
obtained in the range 2–10 mg/L (R2 > 0.99) followed by sample testing. The released MI content
was expressed as cumulative release in µg/cm2. Each PU-MI sample release was studied over seven
parallels and the final reading was calculated average of all parallels.
3.5. In-Vitro Calcification
The calcification solution was prepared using the following formulation: [Na+] = 136.8 mM,
[Cl−] = 144.5 mM, [Ca2+] = 3.87 mM, [HPO42−] = 2.32 mM, [K+] = 1.16 mM. The solution was buffered
in 50 mM Tris buffer at pH = 7.4 and maintained at room temperature. This preparation recipe gave
a calcium concentration similar to the mean level of physiological calcium in serum, with a ratio of
Ca/PO4 = 1.67, identical to hydroxyapatite (HAP). The calcification tests were conducted by incubating
PU and MI-PU films in the calcification medium. Four specimens (20 mm × 10 mm) were cut from
each type of electrospun film type. Each of these specimens were put into four separate bottles, each
containing 20 mL of the calcification solution and incubated for period of 60 days. The bottles were
sealed and placed in a water bath shaker (100 rpm) at 37 ◦C. All specimens were inspected daily during
the entire period of incubation. The calcification solutions were replaced every five days to maintain
electrolyte concentrations and to keep the pH constant. After 60 days, the film samples were taken out
and rinsed four times in distilled water to remove any residual solution and loosely attached deposits.
The samples were then dried in a vacuum oven for 48 hr at room temperature.
3.5.1. Degree of Calcification
Calcified samples were observed for degree of calcification by using Von Kossa and Alizarin Red
S staining techniques. For Von Kossa staining, the films were stained by incubating in 5% silver nitrate
solution in glass beaker for 45 min [75]. During this time, the solution was exposed to bright light using
a 60 watt lamp while the beaker was covered with aluminium foil, to reflect maximum light. This was
followed by rinsing of specimen films in distilled water three times. The samples were then immersed
in 5% sodium thiosulfate for 5 min followed by another again. Finally, the samples were dehydrated
and mounted on coverslips for microscopic analysis. The deposition of HAP crystals was visualised as
black-brown spots on the film surfaces. Separately, the samples were also analysed with Alizarin Red
S method. Alizarin Red S dye (2 gm was dissolved in deionised water (100 mL). The pH was adjusted
to 4.1–4.3 with 10% ammonium hydroxide. Since pH is a critical factor, the solution was made fresh
every time and checked for pH regularly. Specimen films were stained in the solution for 4–5 min and
the reaction was observed microscopically until the orange colour started appearing. The samples
were taken out and blotted carefully to remove excess dye on the surface. Calcium deposits appeared
as a dark red-orange colour.
3.6. Infrared Spectroscopy Analysis
Infrared spectra of films were recorded with an attenuated total reflectance (ATR) FTIR
spectrophotometer (VERTEX 70, Bruker, Billerica, MA, USA). Each spectrum was obtained in
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absorbance mode at 32 scans per piece between 4000 and 500 cm−1 at intervals of 1 cm−1 and with a
resolution of 4 cm−1.
4. Conclusions
This study demonstrated the potential of controlled therapeutic delivery of Mg2+ ions in a PU
nanofibre matrix for inhibition of calcification. Since, replenishment of the drug into the matrix
after exhaustion is not possible in monolithic systems, the long-term (1–2 years) performance of
these functional PU matrices is warranted. The role which Mg plays in the prevention of calcium
crystal deposition on matrix surface can significantly lower the risk of embolic stroke events
caused by a dislodged HAP crystal specifically in vascular implants, as well enhance long-term
implant functionality.
Author Contributions: C.S. and X.W. planned the manuscript. C.S. wrote the manuscript. X.W. commented on
and modified the manuscript.
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